Immuneering Corporation - Class A
News
Immuneering stock rockets 45% on pancreatic therapy data
SeekingAlpha.com: All News Immuneering (IMRX) stock rocketed 45% post-market Thursday after the company reported positive Phase 2a data for its drug candidate IMM-1-104 in the treatment of pancreatic cancer.\n more…
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
Globe Newswire - In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an...\n more…
Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Price Target from Analysts
Ticker Report Shares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat reports...\n more…
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Simply Wall St Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...\n more…
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Globe Newswire CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...\n more…
Short Interest in Immuneering Co. (NASDAQ:IMRX) Decreases By 6.6%
Ticker Report Immuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totalling 2,690,000 shares...\n more…